On October 31, 2022, Singh, Priya; Singh, Neelu; Mishra, Nidhi; Nisha, Raquibun; Alka; Maurya, Priyanka; Pal, Ravi Raj; Singh, Samipta; Saraf, Shubhini A. published an article.Recommanded Product: 380843-75-4 The title of the article was Functionalized bosutinib liposomes for target specific delivery in management of estrogen-positive cancer. And the article contained the following:
This study was designed to create surface-functionalized bosutinib liposomes that could be used for the management of estrogen-pos. cancers. The novelty of this work was the anti-cancer activity of bosutinib-loaded liposomes (Bos-LPs) in estrogen-pos. cancer via estrogen response elements, responsible for the malignancy of cancer cells. Biotin effectively delivers active moiety to tumor tissues because it interacts with the biotin receptor and operates through the Sodium-dependent multivitamin transporters (SMVT) transporter. The prepared liposomes had a 257.73 ± 4.50 nm particle size, – 28.07 ± 5.81 mV zeta potential, 87.78 ± 1.16 % encapsulation efficiency and 85.56 ± 0.95 % drug release for 48 h. The surface architecture of biotin-modified bosutinib-loaded liposomes (b-Bos-LPs) was confirmed using scanning electron and transmission electron microscopies. In-vitro experiments revealed that b-Bos-LPs outperformed Bos and Bos-LPs in terms of significantly reduced cell viability in MCF-7 cells. According to biodistribution and pharmacokinetic studies, b-Bos-LPs have a higher Bos concentration in tumor tissues as compared to the other organs and also possess better pharmacokinetic activity, indicating that they can be used to treat carcinogen-induced estrogen-pos. cancers. This is the first study to show that b-Bos-LPs can display activity against estrogen-pos. cancer via biotin targeting. As evidenced by various parameters, b-Bos-LPs showed improved anticancer targeting, therapeutic safety and efficacy in carcinogen-induced estrogen-pos. cancer. The receptor protein estrogen, which is primarily responsible for this cancer was downregulated by b-Bos-LPs in an immunoblotting assay. The results showed that biotinylated distearoylphosphatidylcholine (DSPC) augmented LPs loaded with Bosutinib can cause apoptosis in estrogen-pos. breast cancer and be an effective way to treat estrogen-pos. cancer. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 380843-75-4
The Article related to bosutinib liposome target specific delivery estrogen breast cancer, bosutinib, breast cancer, estrogen-positive, liposomes, Placeholder for records without volume info and other aspects.Recommanded Product: 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics